This site is intended for health professionals only!

Published on 27 September 2013

Share this story:
Twitter
LinkedIn

Foster Clinical and basic science research in diabetes

 

 

Sanofi (EURONEXT : SAN and NYSE : SNY) and the European Association for the Study of Diabetes (EASD) have announced the award of a research grant from Sanofi to the European Foundation for the Study of Diabetes (EFSD), to establish two new European research programs as part of their ongoing partnership agreement.
The research programs, entitled EFSD/Sanofi European Research Program: Innovative Approaches for the treatment of Type 1 and Type 2 Diabetes and EFSD/Sanofi Program for Collaborative Clinical Diabetes Research between Non-European and European Countrie, will encourage and support research in the field of diabetes, with the aim of improving treatment and increasing collaboration amongst research groups in different countries.
“This research grant marks our continued dedication to advancing research and understanding of diabetes globally,” said Riccardo Perfetti, Chief Medical Officer, Global Diabetes, Sanofi. “Through our partnership with EFSD, we will work towards supporting innovative science and promoting partnership between investigators from different countries with the ultimate objective of helping to improve the lives of people with diabetes worldwide.” 
The research programs goals are to promote increased European research into specific areas of common interest for diabetes, including innovative approaches for treatment. By increasing diabetes research in rapidly developing non-European countries, and encouraging researchers to choose diabetes as a field of study, the programs will stimulate clinical research collaboration with European countries. The programs also aim to support researchers in countries where clinical research is approaching the standard of international excellence, who would particularly benefit from the collaboration with and access to the leading research institutes in Europe.
“EFSD is proud to join forces with Sanofi to thoroughly explore these areas of diabetes research and to bring diabetes to the forefront of research as one of the defining health problems of the 21st century, and one of which, despite the great efforts being made, still remains insufficiently understood,” commented Andrew JM Boulton, President of EASD/EFSD.
The partnership continues a longstanding tradition of collaboration between Sanofi and the EFSD. This research grant agreement awards €1.5m to EFSD and renews their partnership until January 2015, when the grant expires.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn